Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-08-11), Viatris's 1-Year Sharpe Ratio is 2.35.
The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.
The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.
Viatris 1-Year Sharpe Ratio Related Terms
HAM:VIA vs UTHR, NBIX, ELAN: 1-Year Sharpe Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viatris 1-Year Sharpe Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Viatris's 1-Year Sharpe Ratio distribution charts can be found below:
* The bar in red indicates where Viatris's 1-Year Sharpe Ratio falls into.
The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.
Viatris (HAM:VIA) has a 1-Year Sharpe Ratio of 2.35 as of Aug. 11, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Viatris and its competitors.
Is Viatris' 1-Year Sharpe Ratio too high?
Viatris' current 1-Year Sharpe Ratio is 2.35. Overall, Viatris has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viatris' 1-Year Sharpe Ratio compare to UTHR and NBIX?
Viatris' 1-Year Sharpe Ratio of 2.35 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Drug Manufacturers company?
A good 1-Year Sharpe Ratio depends on the Drug Manufacturers industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Viatris and its competitors. Viatris's current 1-Year Sharpe Ratio is 2.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viatris stock overvalued right now?
Based on GuruFocus' analysis, Viatris (HAM:VIA) is currently considered Significantly Overvalued. The stock's GF Value™ is €9.85, compared to a current price of €14.07 — trading 42.8% above its estimated fair value. The current 1-Year Sharpe Ratio is 2.35. Viatris' overall GF Score™ is 66/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Viatris (HAM:VIA), the current 1-Year Sharpe Ratio is 2.35 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viatris (HAM:VIA) Overvalued in 2026?
Based on GuruFocus' analysis, Viatris stock appears to be overvalued.
The current stock price of €14.07 is trading 42.8% above its estimated GF Value™ of €9.85.
GuruFocus considers Viatris to be Significantly Overvalued.
Key valuation signals for HAM:VIA:
1-Year Sharpe Ratio: 2.35
GF Value™: €9.85 vs. price of €14.07 (42.8% above fair value)
No single metric tells the full story. See the HAM:VIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
66GF Score
Get the complete analysis for HAM:VIA
1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:VIA has been successfully added to your 
